APRE News and Press, Aprea Therapeutics Inc. From 08/02/22

BOSTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Ex...

Enveric Biosciences ( ENVB ) -20% announces $8M registered direct offering and private placement, priced at a premium to market under Nasdaq rules. Squarespace ( SQSP ) -13% on Q2 results. Baosheng Media Group Holdings ( BAOS ) -12% . Addex ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the worst scourges of our time, experts estimated that nearly two million new cancer cases were diagnosed last year. However, the advent of advanced therapeutics that the coronavirus pandemic engendered bodes well ...

Shares of micro-cap biotech Aprea Therapeutics ( NASDAQ: APRE ) jumped as much as 32.5% to $1.06 on heavy volume in Friday morning trade, amidst mixed broader markets. Over 20.7M shares of APRE had changed hands as of 1058 ET, well above the stock's 3-month average volum...

Sometimes the best penny stocks to buy are the ones that nobody is looking at (yet). The last few months of stock market trends have certainly shown that anything can happen, and even good news can make a surprising impact on stocks. Today, the latest round of economic data came out thanks ...

Aprea Therapeutics press release (NASDAQ:APRE): Q1 GAAP EPS of -$0.36 beats by $0.02. As of March 31, 2022, the Company had $47.6 million of cash and cash equivalents compared to $53.1 million of cash and cash equivalents as of December 31, 2021. For further details...

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (...

Shares of Aprea Therapeutics Inc. (NASDAQ:APRE) traded at a new 52-week high today of $53.11. This new high was reached on above average trading volume as 58.3 million shares traded hands, while the average 30-day volume is approximately 364,000 shares. Aprea Therapeutics Inc. has overhe...

Aprea Therapeutics press release (NASDAQ:APRE): Q4 GAAP EPS of -$0.36 beats by $0.08. As of December 31, 2021, the Company had $53.1 million of cash and cash equivalents compared to $89.0 million of cash and cash equivalents as of December 31, 2020. For further deta...

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three m...